Evaluation of genetic inactivation of lysine deacetylases KDAC6 (HDAC6) and KDAC8 (HDAC8) versus treatment with KDAC-selective inhibitors

To investigate the specificity and biological impacts of KDAC-selective inhibitors, we treated wild-type HT1080 cells and cell lines containing point mutations that result in endogenous expression of a catalytically-inactive variant with KDAC6 and KDAC8 selective inhibitors Tubastatin A and PCI-34051. Expression profiling analysis was then performed on the treated cells vs. untreated wild HT1080 cells. Comparative gene expression profiling analysis of RNA-seq data for inhibitor-treated HT1080 cells and variants containing inactivated KDACs, with 3 replicates. WT data is included in GSE228549.

为探究组蛋白去乙酰化酶（KDAC）选择性抑制剂的特异性及其生物学效应，我们使用KDAC6与KDAC8选择性抑制剂Tubastatin A和PCI-34051处理野生型HT1080细胞，以及携带可介导催化失活变体内源表达的点突变的细胞系。随后对处理组细胞与未处理的野生型HT1080细胞进行表达谱分析。本研究针对经抑制剂处理的HT1080细胞及KDAC失活细胞变体的RNA测序（RNA-seq）数据开展比较基因表达谱分析，实验设置3次生物学重复。野生型（Wild Type, WT）相关数据已收录于GSE228549数据集。